News just went out on $ISOLF
VANCOUVER, British Columbia, March 12, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive CBD innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that the Company has successfully performed all of the due diligence set out in the binding agreement to acquire the Biosynthesis Pharma Group (BSPG). With this process now complete, the Company anticipates the closing of the acquisition to occur within the next couple of weeks.
Through BSPG’s proprietary industrial scale extraction methodologies, the company produces a high-purity, bioactive CBD isolate at a purity level of 99.5%+ for use in pharmaceutical applications globally to benefit humans and animals suffering from a range of both critical and non-life-threatening illnesses. BSPG currently has the capability of processing over 1.5 metric tons of hemp biomass daily to extract CBD, terpenes and other cannabinoids, specifically CBG.
“Isodiol management and legal teams have done a tremendous job vetting and validating all operating and financial information of the BSPG companies”, stated Marcos Agramont, CEO of Isodiol International Inc. “With this acquisition closing imminently, we will control manufacturing of the world’s purest, most bioactive CBD isolate, and will control a true pharmaceutical grade CBD product that is backed by clinical data from world renowned institutions. The BSPG team has done an incredible job establishing its global operations and with this merger, we are now positioned to change the conversation around the world on CBD and other cannabinoids.”
As the acquisition closes, the Company will begin publishing the various findings from clinicals completed using the BSPG CBD isolate. Publishing this data will coincide with implementing commercialization strategies for the various markets this clinical data can be represented. Teams are currently being assembled in these countries with practitioner education seminars and establishing logistics being the focus.
“The education process needs to start at the government regulator and practitioner levels and Isodiol is committed to this process through various initiatives”, stated Marcos Agramont. “Through our partnership with Livecare we are assembling a team of world-class doctors, researchers and industry professionals in collaborating on research which will be shared through the Livecare interface for the public to access.”
There have been no changes to the acquisition price stated in the news release from December 17th, 2017.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
